CSL Shares Touch Nine-Year Lows as 50% Decline Tests Market Patience

CSL shares (ASX: CSL) extended a brutal 12-month selloff, briefly touching A$122.48 before closing higher at A$124.41 on Tuesday, with the price touching it’s lowest price levels since 2017 and capping a 50% decline that has stunned long-term holders of what was once Australia’s most reliable healthcare compounder.

In a potentially interesting twist, the latest session saw volume ease to just 79% of typical turnover, suggesting some potential exhaustion in the selling pressure that has gripped the stock since August 2025, with bulls hoping to see some support step in. Nevertheless, CSL’s fall from grace represents one of the most dramatic deratings in ASX 200 history for a company that has maintained profitability and dividend growth throughout the downturn.

The catalyst for CSL’s structural reset came in August 2025, when management delivered a mixed FY25 result alongside guidance that disappointed markets accustomed to double-digit earnings growth. More significantly, the company announced plans to demerge its influenza vaccine business, CSL Seqirus, into a separately listed entity while embarking on a major restructuring that would see workforce reductions of up to 15%. The announcement triggered CSL’s worst single-day selloff since its 1994 listing, with shares plunging 15% in one session.

Since that inflection point, a series of operational and governance missteps have compounded market concerns. The Seqirus business has faced what management described as “flu setback” challenges, with underwhelming vaccine performance and margin pressure weighing on sentiment. In February 2026, CSL’s CEO resigned in circumstances that raised eyebrows—the announcement came after hours but while the market was effectively still trading, creating confusion and prompting criticism of governance standards at a company historically viewed as exceptionally well-run.

Despite the carnage in the share price, CSL’s underlying financials tell a more nuanced story. The company continues to generate revenue and profit growth in absolute terms, with FY25 net profit after tax rising from prior-year levels and operating cash flow remaining robust. Dividends per share have increased over time, and management has maintained an active on-market buyback program, with daily purchases continuing through late April and early May 2026 even as the stock tests multi-year lows.

However, return on invested capital has trended lower from above 20% to the low teens, reflecting the capital intensity of recent acquisitions, capacity expansions, and the transitional drag from the Seqirus demerger process. This declining ROIC trajectory has provided ammunition for bears who argue that CSL’s best days of hyper-efficient capital allocation may be behind it, justifying a permanently lower valuation multiple.

The company’s on-market buyback has emerged as the single most cited bullish talking point among value-oriented investors. Management’s willingness to deploy capital at eight- to nine-year lows is viewed by supporters as a strong signal that insiders consider the stock materially undervalued. The buyback also provides technical support and enhances per-share metrics, potentially accelerating earnings-per-share growth once operational fundamentals stabilise.

From a technical perspective, CSL’s five-year price performance now stands at negative 54.68%, with the stock having lagged the broader ASX 200 index substantially throughout 2025 and into 2026.

Market sentiment appears divided between structural bears who believe CSL is transitioning to a “new normal” of mid-teens growth that does not warrant premium valuations, and contrarian bulls who view the 50% drawdown as a once-in-a-cycle entry point for a franchise asset with defensible competitive moats in plasma-derived therapies, specialty biologics, and vaccines. There are potential signs of exhaustion among long-time holders, with some rotating out after riding the stock from above A$300 back to the low A$120s, while others argue the company is now deeply oversold.

Looking ahead, the path from here hinges on execution. Bulls need to see the Seqirus demerger complete smoothly, with clearer earnings profiles and renewed growth in both entities. A normalisation of the flu business and articulation of a convincing medium-term plan by new leadership would help stabilise sentiment. Bears, meanwhile, will watch for any further execution issues during the demerger, continued competitive erosion in core franchises, or additional negative surprises that undermine confidence in management’s ability to navigate the transformation.

With CSL now trading at levels not seen since 2017, the stock has become a litmus test for whether markets will reward patient capital in high-quality healthcare franchises going through cyclical troughs, or whether the company’s premium-compounder days are permanently behind it.